Similar articles

• Ventilation-perfusion relationships in preterm infants after surfactant treatment.

  Bowen W, Martin CR, Krauss AN, Auld PA. Bowen W, et al. Pediatr Pulmonol. 1994 Sep;18(3):155-62. doi: 10.1002/ppul.1950180307. Pediatr Pulmonol. 1994. PMID: 7800432 Clinical Trial.
• [The therapeutic use of pulmonary surfactant in neonatal hyaline membrane disease].

  Lozano-González CH, Piña-Ceballos VM, Beyer-Obezo J, Gutiérrez-Martín A, Martínez-Hinojosa B, Flores-Támez ME. Lozano-González CH, et al. Bol Med Hosp Infant Mex. 1993 Jul;50(7):481-91. Bol Med Hosp Infant Mex. 1993. PMID: 8363747 Spanish.
• [Study of treatment of hyaline membrane disease with pulmonary surfactant replacement in premature infant].

  Ji SP, Zhang XL, Ma WX, Sun YP, Li XH, Yu JH. Ji SP, et al. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2007 Apr;19(4):248. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2007. PMID: 17448287 Clinical Trial. Chinese. No abstract available.
• [Administration of surfactant in hyaline membrane disease].

  Valls i Soler A. Valls i Soler A. An Esp Pediatr. 1987 Sep;27(3):147-51. An Esp Pediatr. 1987. PMID: 3322119 Review. Spanish. No abstract available.
• [Anti-atelectasis factor (surfactant) and hyaline membrane disease in premature infants].

  Saule H. Saule H. Med Klin. 1975 Mar 7;70(10):409-15. Med Klin. 1975. PMID: 1091827 Review. German. No abstract available.